| Alive (N=169) |
Deceased (N=142) |
Overall (N=311) |
|
|---|---|---|---|
| Sex | |||
| Female | 81 (47.9%) | 65 (45.8%) | 146 (46.9%) |
| Male | 88 (52.1%) | 77 (54.2%) | 165 (53.1%) |
| Race | |||
| Asian | 7 (4.1%) | 3 (2.1%) | 10 (3.2%) |
| Black or African American | 13 (7.7%) | 13 (9.2%) | 26 (8.4%) |
| Other | 8 (4.7%) | 6 (4.2%) | 14 (4.5%) |
| White | 141 (83.4%) | 120 (84.5%) | 261 (83.9%) |
| CCI | |||
| Mild | 123 (72.8%) | 99 (69.7%) | 222 (71.4%) |
| Moderate | 26 (15.4%) | 24 (16.9%) | 50 (16.1%) |
| Severe | 18 (10.7%) | 17 (12.0%) | 35 (11.3%) |
| Missing | 2 (1.2%) | 2 (1.4%) | 4 (1.3%) |
| Malignancy | |||
| ALL | 19 (11.2%) | 20 (14.1%) | 39 (12.5%) |
| AML | 74 (43.8%) | 67 (47.2%) | 141 (45.3%) |
| Aplastic anemia | 7 (4.1%) | 0 (0%) | 7 (2.3%) |
| CLL | 3 (1.8%) | 1 (0.7%) | 4 (1.3%) |
| CML | 5 (3.0%) | 7 (4.9%) | 12 (3.9%) |
| Hodgkin's lymphoma | 4 (2.4%) | 5 (3.5%) | 9 (2.9%) |
| Multiple Myeloma | 2 (1.2%) | 0 (0%) | 2 (0.6%) |
| Myelodysplastic syndrome | 30 (17.8%) | 28 (19.7%) | 58 (18.6%) |
| Myeloproliferative disorders | 4 (2.4%) | 6 (4.2%) | 10 (3.2%) |
| Non-Hodgkin's Lymphoma | 3 (1.8%) | 0 (0%) | 3 (1.0%) |
| Other | 18 (10.7%) | 8 (5.6%) | 26 (8.4%) |
| HLA Match | |||
| 7/8 or less | 4 (2.4%) | 6 (4.2%) | 10 (3.2%) |
| 8/8 | 163 (96.4%) | 136 (95.8%) | 299 (96.1%) |
| Missing | 2 (1.2%) | 0 (0%) | 2 (0.6%) |
| Conditioning regimen | |||
| Busulfan based regimen (MAC) | 39 (23.1%) | 34 (23.9%) | 73 (23.5%) |
| Others | 11 (6.5%) | 12 (8.5%) | 23 (7.4%) |
| Reduced BU/TBI (RIC) | 111 (65.7%) | 87 (61.3%) | 198 (63.7%) |
| TBI based regimen | 6 (3.6%) | 9 (6.3%) | 15 (4.8%) |
| Missing | 2 (1.2%) | 0 (0%) | 2 (0.6%) |
| Donor | |||
| Match related | 78 (46.2%) | 62 (43.7%) | 140 (45.0%) |
| Match unrelated | 91 (53.8%) | 80 (56.3%) | 171 (55.0%) |